Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So far this month they have four posts on Facebook about the tests and it's only the 15th of July .. last month there were three. They sure seem like they are selling them. I have emailed them on their info link and ask them if they were and if they could provide the website link and I have not received a response back as of today.
I thought that you were talking about the launch of the covid business that was a few months away late in 2020.
No, I'm referring to the Official launch of the Dry Eye Business that was a few weeks away a month or two ago.
You'e referring to the Earnings report? Did they post a delay .. again?
One thing For Sure about AXIM they are never Early.
This is a nice PR. I'm glad that the dry eye product doesn't require much tearing to work. It would be disapointing if it only worked on wet eyes. My humor aside It is a good well written pitch.
Unfortunately this is an AD .. payed advertisement. When do we get real news and not the payed for news?
https://www.benzinga.com/markets/penny-stocks/22/07/27981723/will-this-dry-eye-rapid-test-prove-to-be-a-rapid-success
Ho back to sleep
Oh nuts, it has fallen down again. I am sure the so called smart buyer at 0.06 was not so smart after all. Tail of the tape shows what is going on. Relying on the stock performance while one hibernates, surrounded by solid walls, will elicit a negative response once released from the slumbers that actions bring. With the renewed upsurge in Covid cases I wonder if the old Immunopass (more like Immunofail) story will be flying around again trying to gather renewed support. Perhaps they can rename the dry eye product to something more impactful to compete in a marketing here today, marketing gone tomorrow-perhaps a tag line like "before this there was never a dry eye in the house". They need assistance to help investors build a nest to sleep in.
Just like MJNA, this is going below 0.01. Management is too greedy at the expense of shareholders.
This stock has been a disappointment for me but I haven't thrown in the towel yet.
Since you asked I have transitioned here from Stocktwits.
Are new or just changed your name?
It seems that as soon as that post came the stock started drifting downward.
Good question. I was wondering about that post myself.
Why do you think it will go past .15 soon?
This can go past .15 soon.
There you go. This is off my screen taking a breather and off to z Portugal on the train to visit friends in Lisbon then off to Porto and drive the Roman Way. You guys have fun. Hope John is okay and all this gets put behind him. Peace.
Word!
No sure if this an update on their site but they just posted it on the Meta Internet's :)
Have a good weekend .. most of you
https://aximbiotech.com/axim-eye/
Mepublican mantra.
"You guys may not be following the internet the way I do!"
It's a spec investment and to trade it, well you have to be nimble and quick and take advantage of bullshit posts that attract flies. The OTC is littered with the empty bank accounts of marks.
We are already over 1 million shares traded this morning .. looks 50/50 on who's sellin and buyin so far
Those two professions suffer from dry eye-noted-even. Waiting for pronouncements from the silent radar flyer on this one. Was it so smart someone bought out of the gate yesterday? Time will tell.
Right I mean if doctors and bodybuilders are buying the stock this thing could takeoff to dah moooooon
Could be the Doctor and the Bodybuilder.
A very smart investor buying right out of the gate this morning.
Who defrauded investors? The so called billionaires or others like DD SUMMIT. Remember it takes skill and some luck to be a successful trader.
My own opinion is that there was a coordinated effort to defraud Investors....I think.there needs to be a substantial amount of incarceration to attone for that. However, that is just my opinion.
That's interesting. It reads almost like some of John's videos from late 2020. Time is not what most people think it is. The past, present and future coexist on the hologram.
Not to bring up the past but there seems to be an interest again in immunity levels.
https://www.msn.com/en-us/health/medical/a-simple-blood-test-could-reveal-how-strong-your-covid-immunity-is/ar-AAYykbH?ocid=msedgdhp&pc=W012&cvid=d1b94c43fa454cdba900adb33ff13f19
Hoping this misadventure will be put behind him and he has learned from it. His family will survive intact which is great-a son needs his father and a wife her husband, and he will need them both. I wish him well on his future after this incident.
And now for something completely different.
He has a sentencing date in a few months, he won't be able to post after that.
No need to worry. John is "Staying Cool and Staying Awesome". Its good to see him smiling and happy again.
Did you ever receive a satisfactory response to the kit manufacturing now it became clear Immunopass was Immunofail and DED was to help wipe away those tears of dissapointment?
You should discuss that with your legal counsel.
Does it mean that AXIM is likely a scam because BLSQ was promoting the business prospects here?
Yes but that should not imply Axiom is a scam, that would be quite a leap. He was heavily involved with another company that was delisted but I doubt whether he had the same pull with insiders of Axiom.
so, John Drago, was Squirrel, the same person going to jail (likely), was moderating this board?!?!?!!?!
...sometimes wolves in sheeps clothing are difficult to identify...
The government writes in response to the United States Department of Probation’s May 17, 2022 Presentence Investigation Report (“PSR”) concerning the above captioned case. Paragraph 28 of the PSR incorrectly deducts one point from the defendant’s Total Offense Level based upon the defendant’s “timely acceptance of responsibility.” (See PSR at ¶ 28 (citing U.S.S.G. § 3E1.1(b)). As set forth in the parties’ Plea Agreement, however, the government will not be making a motion for an additional point deduction.
This is because the government expended significant effort in preparing for trial in this case, including litigating the admissibility of more than 250 exhibits in two complex pre-trial suppression hearings.
In addition, the PSR contains inaccurate information concerning the defendant’s military record. (See PSR at ¶62). To provide the Court with correct information concerning the defendant’s time in the military, the government will be filing an additional letter and documents obtained from the United States Army under seal."
Sentencing set for 10/21/2022 at 02:00 PM in Courtroom 940 before Judge Gary R. Brown. Ordered by Judge Gary R. Brown on 6/3/2022.
AXIM board content is certainly tainted
Yes and he was formerly known as The Lieutenant before switching his nic to Blind Squirrel.
Squirrel Boy = John Drago?????
Followers
|
105
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5265
|
Created
|
04/29/14
|
Type
|
Free
|
Moderators Blue Skys Squirrel Hunter |
Unlike currently available serological COVID-19 tests that detect an antibody response to the virus, AXIM’s rapid 10-minute test measures a specific subpopulation of antibodies to block binding of the virus to host cell receptors. While there are expensive, time consuming laboratory tests that measure neutralizing antibodies, NeuCovixTM differs in that it is a portable, low cost, rapid point-of-care test with results in 10 minutes.
“We are hopeful our test fills an important need in these uncertain times. While other tests merely show whether someone was infected with coronavirus, we took it a step further by creating a test that stratifies individuals into those who have neutralizing antibodies, which are essential in preventing reinfection, and those who don’t. The test can be deployed for point of care use in convalescent plasma transfusions to severely ill patients and for evaluating efficacy of upcoming vaccines in generating protective antibodies,” said Sergei Svarovsky, PhD, MBA, AXIM’s CSO and co-inventor of NeuCovixTM.
An immediate application of NeuCovixTM, a point-of-care test, is to measure levels of neutralizing antibodies in convalescent plasma so that plasma with the highest levels of neutralizing antibodies can be identified and administered to patients fighting COVID-19. Without this knowledge, many patients could be undertreated with non-neutralizing plasma and may not benefit from this treatment.
Another application of NeuCovixTM is to help ensure that vaccines elicit high levels of neutralizing antibodies. When a vaccine is available, manufacturers can employ the NeuCovixTM rapid, point-of-care test to evaluate protective immune responses in vaccine recipients.
AXIM® Biotech CEO John W. Huemoeller II commented, “Our goal was to make this test, accurate, fast and relatively inexpensive so it could serve as an ‘Immunity Passport port™’ for vaccine developers around the world as they begin larger Phase II and III clinical trials. We are optimistic that NeuCovixTM will be widely used, becoming the gold standard in assessing levels of immunity.”
Doug Lake, Ph.D. and co-inventor of NeuCovixTM commented, “Everybody who recovers from COVID-19 makes antibodies against the virus, but since all antibodies are not created equal, you really want to know if the antibodies you make neutralize the virus. People who recover want to make sure they are protected from re-infection and that they won’t infect others.”
AXIM also announced the filing of a pre-Emergency Use Authorization Application (EUA) and has already initiated dialogue with the FDA in order to finalize its EUA submission. The intellectual property relating to the novel serological test is the subject of Provisional Patent Application No. 63/023,646 “Convalescent Plasma Testing and Treatment” filed on May 12, 2020.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The Company is also developing novel antibodies for therapeutic and diagnostic uses for oncological therapeutics. For more information, please visit www.AXIMBiotech.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |